

Dr. Terance W. Hart

Dr. Terance Hart was appointed Chief Scientific Officer (CSO), at Geistlich Pharma AG in June 2010. He leads and is responsible for the whole R&D departments, for the Raw Material Production, all activities of Medical Director and Global Projects and for the IP department.

Prior to joining Geistlich Pharma AG, he was Head of Chemistry at Vernalis in UK from 2007–2009. From 2005-2007 he was Director of Medicinal Chemistry at Peakdale Molecular with responsibility for all aspects of the medicinal chemistry and drug discovery research. At Novartis (1998–2005) he led the Discovery Chemistry team and shared responsibility for running the Novartis Institute in London and the management of the Nervous System portfolio. He was also a core member of the Global Discovery Chemistry team. He held the position as Director of Chemistry from 1995-1998 at Peptide Therapeutics in Cambridge, UK. Whilst working at Sanofi-Aventis in London (1978-1995) has was Programme Director Cardiovascular Research and had a key role whilst working in France in the clinical development of Taxotere.

Dr. Hart holds a Bachelor of Science from Manchester University in UK and a PhD in Organic Chemistry from the University in Manchester, UK.